120 related articles for article (PubMed ID: 38869192)
1. Noninvasive Transdermal Administration of mRNA Vaccines Encoding Multivalent Neoantigens Effectively Inhibits Melanoma Growth.
Hou Y; Wang Z; Chen Z; Shuai L; Pei Y; Sun B; Jiang Y; Wang H
ACS Biomater Sci Eng; 2024 Jul; 10(7):4587-4600. PubMed ID: 38869192
[TBL] [Abstract][Full Text] [Related]
2. Transcutaneous tumor vaccination combined with anti-programmed death-1 monoclonal antibody treatment produces a synergistic antitumor effect.
Song X; Jiang Y; Zhang W; Elfawal G; Wang K; Jiang D; Hong H; Wu J; He C; Mo X; Wang H
Acta Biomater; 2022 Mar; 140():247-260. PubMed ID: 34843953
[TBL] [Abstract][Full Text] [Related]
3. CpG Oligodeoxynucleotide Developed to Activate Primate Immune Responses Promotes Antitumoral Effects in Combination with a Neoantigen-Based mRNA Cancer Vaccine.
Li Q; Ren J; Liu W; Jiang G; Hu R
Drug Des Devel Ther; 2021; 15():3953-3963. PubMed ID: 34566407
[TBL] [Abstract][Full Text] [Related]
4. Enhanced antitumor immunity by targeting dendritic cells with tumor cell lysate-loaded chitosan nanoparticles vaccine.
Shi GN; Zhang CN; Xu R; Niu JF; Song HJ; Zhang XY; Wang WW; Wang YM; Li C; Wei XQ; Kong DL
Biomaterials; 2017 Jan; 113():191-202. PubMed ID: 27816821
[TBL] [Abstract][Full Text] [Related]
5. Type I-polarized BRAF-pulsed dendritic cells induce antigen-specific CD8+ T cells that impact BRAF-mutant murine melanoma.
Cintolo JA; Datta J; Xu S; Gupta M; Somasundaram R; Czerniecki BJ
Melanoma Res; 2016 Feb; 26(1):1-11. PubMed ID: 26451873
[TBL] [Abstract][Full Text] [Related]
6. Solid-in-Oil Peptide Nanocarriers for Transcutaneous Cancer Vaccine Delivery against Melanoma.
Wakabayashi R; Sakuragi M; Kozaka S; Tahara Y; Kamiya N; Goto M
Mol Pharm; 2018 Mar; 15(3):955-961. PubMed ID: 29397746
[TBL] [Abstract][Full Text] [Related]
7. New generation of DNA-based immunotherapy induces a potent immune response and increases the survival in different tumor models.
Lopes A; Bastiancich C; Bausart M; Ligot S; Lambricht L; Vanvarenberg K; Ucakar B; Gallez B; Préat V; Vandermeulen G
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795383
[TBL] [Abstract][Full Text] [Related]
8. TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma.
De Keersmaecker B; Claerhout S; Carrasco J; Bar I; Corthals J; Wilgenhof S; Neyns B; Thielemans K
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32114500
[TBL] [Abstract][Full Text] [Related]
9. A universal anti-cancer vaccine: Chimeric invariant chain potentiates the inhibition of melanoma progression and the improvement of survival.
Sharbi-Yunger A; Grees M; Cafri G; Bassan D; Eichmüller SB; Tzehoval E; Utikal J; Umansky V; Eisenbach L
Int J Cancer; 2019 Feb; 144(4):909-921. PubMed ID: 30106470
[TBL] [Abstract][Full Text] [Related]
10. Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.
Xia D; Zheng S; Zhang W; He L; Wang Q; Pan J; Zhang L; Wang J; Cao X
J Mol Med (Berl); 2003 Sep; 81(9):585-96. PubMed ID: 12937899
[TBL] [Abstract][Full Text] [Related]
11. Multiple antigen-engineered DC vaccines with or without IFNα to promote antitumor immunity in melanoma.
Butterfield LH; Vujanovic L; Santos PM; Maurer DM; Gambotto A; Lohr J; Li C; Waldman J; Chandran U; Lin Y; Lin H; Tawbi HA; Tarhini AA; Kirkwood JM
J Immunother Cancer; 2019 Apr; 7(1):113. PubMed ID: 31014399
[TBL] [Abstract][Full Text] [Related]
12. MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanoma.
Engelhard VH; Obeng RC; Cummings KL; Petroni GR; Ambakhutwala AL; Chianese-Bullock KA; Smith KT; Lulu A; Varhegyi N; Smolkin ME; Myers P; Mahoney KE; Shabanowitz J; Buettner N; Hall EH; Haden K; Cobbold M; Hunt DF; Weiss G; Gaughan E; Slingluff CL
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32385144
[TBL] [Abstract][Full Text] [Related]
13. T Cells Modified with CD70 as an Alternative Cellular Vaccine for Antitumor Immunity.
Lee SE; Shin AR; Sohn HJ; Cho HI; Kim TG
Cancer Res Treat; 2020 Jul; 52(3):747-763. PubMed ID: 32065848
[TBL] [Abstract][Full Text] [Related]
14. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
15. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
[TBL] [Abstract][Full Text] [Related]
16. Adoptive transfer of siRNA Cblb-silenced CD8+ T lymphocytes augments tumor vaccine efficacy in a B16 melanoma model.
Hinterleitner R; Gruber T; Pfeifhofer-Obermair C; Lutz-Nicoladoni C; Tzankov A; Schuster M; Penninger JM; Loibner H; Lametschwandtner G; Wolf D; Baier G
PLoS One; 2012; 7(9):e44295. PubMed ID: 22962608
[TBL] [Abstract][Full Text] [Related]
17. Combination Cancer Immunotherapy with Dendritic Cell Vaccine and Nanoparticles Loaded with Interleukin-15 and Anti-beta-catenin siRNA Significantly Inhibits Cancer Growth and Induces Anti-Tumor Immune Response.
Kheshti AMS; Hajizadeh F; Barshidi A; Rashidi B; Ebrahimi F; Bahmanpour S; Karpisheh V; Noukabadi FK; Kiani FK; Hassannia H; Atyabi F; Kiaie SH; Kashanchi F; Navashenaq JG; Mohammadi H; Bagherifar R; Jafari R; Zolbanin NM; Jadidi-Niaragh F
Pharm Res; 2022 Feb; 39(2):353-367. PubMed ID: 35166995
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of T-Cell Responses Against Shared Melanoma Associated Antigens and Predicted Neoantigens in Cutaneous Melanoma Patients Treated With the CSF-470 Allogeneic Cell Vaccine Plus BCG and GM-CSF.
Podaza E; Carri I; Aris M; von Euw E; Bravo AI; Blanco P; Ortiz Wilczyñski JM; Koile D; Yankilevich P; Nielsen M; Mordoh J; Barrio MM
Front Immunol; 2020; 11():1147. PubMed ID: 32582212
[TBL] [Abstract][Full Text] [Related]
19. Regulation gene expression of miR200c and ZEB1 positively enhances effect of tumor vaccine B16F10/GPI-IL-21 on inhibition of melanoma growth and metastasis.
Wang X; He X; Zhao F; Wang J; Zhang H; Shi F; Zhang Y; Cai K; Dou J
J Transl Med; 2014 Mar; 12():68. PubMed ID: 24625224
[TBL] [Abstract][Full Text] [Related]
20. Intralymphatic dendritic cell vaccination induces tumor antigen-specific, skin-homing T lymphocytes.
Grover A; Kim GJ; Lizée G; Tschoi M; Wang G; Wunderlich JR; Rosenberg SA; Hwang ST; Hwu P
Clin Cancer Res; 2006 Oct; 12(19):5801-8. PubMed ID: 17020987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
